Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s What Happened

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped down prior to trading on Thursday. The stock had previously closed at $3.69, but opened at $3.38. Inventiva shares last traded at $3.7150, with a volume of 1,531,710 shares.

Analysts Set New Price Targets

IVA has been the topic of a number of research analyst reports. Guggenheim boosted their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $15.14.

Inventiva Trading Down 2.8%

The company has a debt-to-equity ratio of 0.90, a current ratio of 3.81 and a quick ratio of 3.16. The stock’s 50-day moving average price is $4.37 and its two-hundred day moving average price is $4.69.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million for the quarter. On average, analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVA. NEXTBio Capital Management LP bought a new stake in Inventiva during the 4th quarter valued at about $6,039,000. Propel Bio Management LLC bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $4,650,000. Eventide Asset Management LLC bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $1,155,000. Seven Fleet Capital Management LP purchased a new position in Inventiva in the 1st quarter worth approximately $1,111,000. Finally, Persistent Asset Partners Ltd bought a new position in Inventiva in the 4th quarter valued at approximately $603,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.